KRAS mutation
Lumakras-Vectibix combo outperforms standard therapy in KRAS G12C-mutated colorectal cancer (ESMO 2023)
Anika Sharma
ESMO 2023: LBA10 Nevertheless, a shadow has been cast over the KRAS inhibitor due to recent criticisms by FDA advisors. ...
Roche’s Latest KRAS Data Shows Promise Against Amgen and Mirati, Yet Verdict Remains Uncertain
Anika Sharma
Roche has presented compelling new data showcasing its KRAS inhibitor, divarasib, as a potential contender against rivals Amgen and Mirati. ...
FDA Convenes Advisors to Assess Full Approval Prospects for Amgen’s Lumakras Amid KRAS Uncertainties
Anika Sharma
Amgen faces a critical juncture with its pioneering KRAS inhibitor, Lumakras, as uncertainties loom over its potential combinability with standard ...
